. Heatmap plot of SEQUENoM EpitYpEr DNA methylation results generated from 85 cases of B cell ALL with matching leukemic and remission bone marrow samples, controls (DoNor) and cancer cell line (rEH). DNA methylation data for a total of 103 CpG sites encompassing 15 probes we selected by infinium analysis are shown here (x-axis). DNA hypermethylation of 77/85 (91%) leukemic bone marrow samples was observed regardless of ALL subtype suggesting the existence of a DNA methylation signature associated with leukemia.
Introduction
Pre-B cell acute lymphoblastic leukemia (pre-B ALL) is the most prevalent leukemia in children. The most common chromosomal abnormalities associated with pre-B ALL are t (12;21) , resulting in the ETV6-RUNX1 fusion gene, and hyperdiploidy (>50 chromosomes). A substantial proportion of cases have an apparently cytogenetically normal karyotype. 1 Evidence suggests that the ETV6-RUNX1 fusion gene can arise in utero 2 but is insufficient in isolation to cause malignancy. 3 Cooperating mutations are likely required for progression to leukemia and mutation and copy number aberration in genes involved in B-lymphoid development, including PAX5, IKZF1 and TCF3, are present in up to 40% of ETV6-RUNX1 cases. 4 As these events do not account for all cases, we hypothesized that epigenetic dysregulation may constitute an additional oncogenic hit leading to leukemogenesis. Previous studies have described aberrant promoter DNA methylation of tumor suppressor genes including E-cadherin, DKK and p16 in childhood pre-B ALL. 5 To date, there has been little consensus concerning locus-specific DNA methylation in childhood ALL due to the range of methods used to measure DNA methylation on disparate combinations of distinct subgroups of ALL. 6 pre-B cell acute lymphoblastic leukemia (ALL) is the most prevalent childhood malignancy and remains one of the highest causes of childhood mortality. Despite this, the mechanisms leading to disease remain poorly understood. We asked if recurrent aberrant DNA methylation plays a role in childhood ALL and have defined a genome-scale DNA methylation profile associated with the ETV6-RUNX1 subtype of pediatric ALL. Archival bone marrow smears from 19 children collected at diagnosis and remission were used to derive a disease specific DNA methylation profile. the gene signature was confirmed in an independent cohort of 86 patients. A further 163 patients were analyzed for DNA methylation of a three gene signature. We found that the DNA methylation signature at diagnosis was unique from remission. fifteen loci were sufficient to discriminate leukemia from disease-free samples and purified CD34 + cells. DNA methylation of these loci was recurrent irrespective of cytogenetic subtype of pre-B cell ALL. We show that recurrent aberrant genomic methylation is a common feature of pre-B ALL, suggesting a shared pathway for disease development. By revealing new DNA methylation markers associated with disease, this study has identified putative targets for development of novel epigenetic-based therapies.
Results
Our initial experiments using SEQUENOM EpiTYPER confirmed the stability of DNA methylation between matched cryopreserved bone marrow and archived bone marrow taken from the same individual (Pearson's correlation coefficient = 0.97, Fig. S1 ). As a first step toward fully examining the degree of epigenetic disruption associated with pediatric ALL, we measured DNA methylation at 27,578 CpG sites on DNA extracted from microscope slide archived primary bone marrow aspirates from ETV6-RUNX1 positive pediatric ALL cases. To identify diseasespecific changes in DNA methylation, we directly compared samples taken at diagnosis, matching 28-day post induction (remission sample) and long-term follow-up archived primary bone marrow aspirates taken up to a year post induction (follow up).
Genome-scale DNA methylation was profiled in 19 children diagnosed with ETV6-RUNX1 pre-B ALL who are currently in remission (11 male, 8 female), of which 16 children had matching leukemic and remission bone marrow samples for comparison ( performance of these three methods using 3-fold cross-validation, iterated ten times revealed that DNA methylation of at least 15 CpG sites could discriminate leukemic from disease-free bone marrow samples with 100% accuracy (Fig. S3) . To increase our confidence in identifying a disease-specific DNA methylation profile and to select potential candidate markers for validation, we identified 115 (57.5%) common probes ranked within the top 200 probes by each method of feature selection ( Fig. S4 and Table S1 ). We found a robust and distinct DNA methylation pattern that discriminates leukemia from matching remission bone marrow and healthy controls ( Fig. 2 ; Table S2 ). The leukemic DNA methylation pattern was distinct from CD34 + , CD19 + , CD33 + and CD34/CD19/CD33 negative cell fractions, which were more similar to primary remission marrow supporting the existence of a leukemia-specific DNA methylation profile (Fig. 2) . The majority of discriminating probes (112/115, 97%) were hypermethylated in leukemic bone marrow (Fig. 3) . As the Infinium methylation array platform focuses on gene promoters, the observed hypermethylation in leukemic bone marrow suggests the potential for recurrent aberrant expression of associated genes.
Ingenuity Pathway Analysis (Ingenuity ® Systems, www. ingenuity.com) of the associated genes revealed enhanced representation of genes involved with developmental processes, cellular differentiation and cancer. This was supported by DAVID analysis 7 to reveal a range of transcription factors implicated CD33 -Fluorescence Activated Cell Sorted (FACS) fractions from unrelated healthy donor children. Leukemic (CCRF-CEM, REH and K562) and solid cancer cell lines [MCF-7 (breast), SW48 (colon)] were also analyzed for genome scale DNA methylation for comparative purposes (Fig. 1) .
DNA methylation probes with p value detection of less than 0.05 across all samples (14,876 probes) were analyzed for initial exploratory analysis. We observed a higher average methylation level (β-value) across all probes analyzed in the ETV6-RUNX1 leukemic bone marrow samples [0.29 ± 0.04 (SD)] when compared with remission (0.22 ± 0.01, paired Student's t-test with Bonferroni Correction for multiple testing p = 0.049) and disease-free control marrow samples (0.24 ± 0.01), indicative of global gene promoter hypermethylation of the leukemic genome (Fig. S2) .
Unsupervised hierarchical clustering of the 14,876 probes clearly delineated primary leukemia bone marrow from remission bone marrow and non-leukemic control samples (Fig. 1) .
A DNA methylation signature specific to ETV6-RUNX1 leukemic bone marrow was then defined using three methods of supervised machine learning analysis for classifier and feature selection. These methods were applied to the entire data set (27,578 probes) to identify a core set of ranked DNA methylation probes that reliably discriminate between leukemic and matched remission bone marrow samples (details of the methods used are outlined in the Supplemental Mataterial). The classification with genome-wide gene expression analysis. By comparing with a publically available data set from a pediatric B cell ALL study of gene expression, 15 we investigated the gene expression status of the top 200 differentially methylated genes we identified using RFE-SVM. We were able to compare our DNA methylation results with associated gene expression on 99 genes. We found 12 unmethylated leukemic genes were expressed in ETV6-RUNX1 leukemia cases while most of the remaining genes were methylated and silenced. In addition to TCF3, we found POU2AF1 and RAG1 were unmethylated and expressed in ETV6-RUNX1 leukemia cases (Table S4) . RAG1 is an essential factor for Ig rearrangement and B cell differentiation.
16 POU2AF1 along with BTG4 have been implicated in chronic lymphocytic leukemia previously 17 and expression of POU2AF1 has been found to have prognostic significance in myeloma 18 and lymphoma. 19 However, their role in pediatric B cell ALL remains to be characterized. The gene expression profile of these 12 genes remained after extending to all B cell leukemia subtypes that were analyzed by Yeoh et al. (Fig. S5) .
Our feature selection analysis demonstrated that at least 15 CpG methylation features are required to distinguish leukemia from remission samples (Fig. S3A) . For replication of our microarray results, we selected 15 of the 115 common probes for SEQUENOM EpiTYPER analysis on 85 childhood B cell leukemia cases with matching leukemic and remission bone marrow aspirates (Fig. 4) . The selected cases represented a range of in cell fate commitment, gene regulation and DNA binding (Table S3) where DNA methylation may have impaired gene function through transcription silencing or activation. We identified hypermethylation of CpG sites associated with genes previously implicated in cancer and leukemia including MYOD1, 8 
PTPRZ1, PPARG
9 and SFRP1. 10 We also found hypermethylation of associated genes not previously implicated in cancer or leukemia. These include promoter methylation of genes encoding FOXE3, a forkhead transcription factor required for eye development (reviewed in ref. 11), f-box protein FBXO39 and signaling receptor PKDREJ. Genes important in hematopoiesis were also identified, including aberrant methylation of TCF3, 12 EGR4
13
and BTG4 in the leukemic samples. TCF3 is an important transcription factor for B cell differentiation and is the translocation gene partner in t(1;19) ALL. 1 With the exception of TCF3, which was hypomethylated in leukemic samples, we did not find coordinate DNA methylation of genes such as PAX5 or IKZF1. 4 However, TLX3 (HOX11L2), a critical gene in childhood T-cell leukemia that is activated 14 and frequently mutated, 1 was commonly hypermethylated in our B cell leukemic samples (Tables  S1 and S2 ). The recurrent dysregulation of DNA methylation we observe here suggests that common gene pathways are affected by DNA methylation that could contribute the required second oncogenic hit for leukemogenesis.
As the samples we used here were more akin to formalin fixed paraffin embedded (FFPE) material, they were not compatible types, our comparisons with FACS purified CD34 + , CD33 + and CD19 + cells from healthy bone marrow, representing undifferentiated hematopoietic cells, myeloid cells and differentiated B cells respectively, show remarkable similarity in DNA methylation profile to the remission samples analyzed. These disease-specific DNA methylation markers correlate with associated gene expression. We found aberrant methylation of critical genes involved in B cell development and hematopoiesis were concordant with aberrant gene expression from an independent study. 15 This supports a regulatory role of aberrant DNA methylation on gene expression in pediatric B cell ALL. Furthermore, the DNA methylation signature we have identified by genomescale DNA methylation analysis of ETV6-RUNX1 B cell ALL exists in the majority of all other subtypes of B cell ALL we analyzed. Our observation suggests that we have identified a pan B cell ALL DNA methylation signature. The expression status of genes associated with this signature correlated with the DNA methylation state, which also applied to other B cell ALL subtypes. Most of these genes have not been previously implicated in pediatric B cell ALL making these biomarkers an area of interest for future studies.
Our DNA methylation profile will enable the distinction to be made between leukemic and non-leukemic samples based on pediatric ALL subtypes categorized according to cytogenetic karyotyping that include ETV6-RUNX1, hyperdiploidy, normal karyotype and other rare subtypes (Fig. 4) . Strikingly, DNA hypermethylation of these 15 probes were able to clearly discriminate leukemic from remission bone marrow regardless of ALL subtype in 77/85 (91%) cases, demonstrating that recurrent DNA hypermethylation is a common feature of pediatric B cell ALL (Fig. 4) . The remaining 8/85 (9%) cases that were misclassified comprised of cases with abnormal chromosome number (hypodiploidy). When a further 163 pediatric B cell ALL cases were analyzed at the C1orf76, FBXO39 and MYOD1 genes, DNA hypermethylation was still observed (151/163, 93%) in leukemic bone marrow samples (Fig. S6) confirming the existence of a pan-DNA methylation signature in pediatric B cell ALL.
Discussion
We have identified a set of recurrent DNA methylation changes associated with pre-B cell ALL regardless of cytogenetic subtype when compared with matching remission bone marrow samples. Although these methylation differences may be attributed to differences in cellular composition due to remission bone marrow samples consisting of heterogeneous and differentiated cell Figure 2 . Unsupervised clustering heatmap plot of the DNA methylation β-values from the illumina infinium HumanMethylation27 BeadArray of 115 ALL-specific probes identified using three supervised learning methods (x-axis) ( Table S2) . three distinct clusters comprising the leukemia, remission/ non-leukemic and the cell lines are apparent (y-axis).
could potentially be targeted by therapeutic reagents designed to demethylate DNA, some of which are currently being used in adult leukemia and therefore presents a novel avenue for the treatment, diagnosis and monitoring of pediatric pre-B ALL in the future.
Materials and Methods
Patient samples. This study was reviewed and approved by the Royal Children's Hospital Human Research Ethics Committee (HREC27138). Archived bone marrow aspirate microscope slides were used to obtain genomic DNA. After incubation in xylene to remove the coverslip and resin, the smear was scraped off the microscope slide in the presence of lysis buffer and proteinase K. Standard phenol-chloroform extraction and ethanol precipitation was performed to isolate genomic DNA. Genomic DNA from flash frozen bone marrow samples collected from healthy children and cells isolated using Fluorescence Activated Cell Sorting (FACS) with antibodies against CD34, CD19 and CD33 were also extracted using standard phenol-chloroform extraction.
Illumina infinium humanmethylation27 bead array analysis. Genomic DNA from the selected samples were hybridized an "epigenotype" that could potentially overcome some of the technical limitations associated with current minimal residual disease detection methods. 20 For example, PCR-based DNA rearrangement assays currently require a laborious patient-bypatient workup, while fluorescence activated cell sorting (FACS) methods are susceptible to false positive and false negative detection. A sensitive, multilocus DNA methylation assay specific to all subtypes of B cell leukemia would have enhanced specificity and alleviate the need for patient specific workup.
Many of these aberrantly methylated CpG sites may be important contributors to leukemogenesis either through silencing or activation of associated genes. The genes identified in this study are distinct from other genome-scale DNA methylation analyses of cancer [21] [22] [23] and have not been described in pediatric B cell ALL previously. Our study opens up new opportunities for exploring linkages between gene dysregulation, DNA methylation and pediatric pre-B ALL. Importantly it suggests that despite pediatric ALL cases having disparate primary cytogenetic lesions, most share recurrent DNA methylation changes within common pathways likely to be involved in pathogenesis, raising the possibility that all forms of this disease may have a common secondary trigger mediated by DNA methylation. As DNA methylation is a reversible modification, this signature SEQUENOM EpiTYPER analysis of locus specific DNA methylation. Genomic DNA was subjected to bisulfite conversion using MethylEasy Xceed Bisulfite Modification Kit (Human Genetic Signatures). Converted DNA was eluted with sufficient volume of elution buffer to give a final sample concentration of 20 ng/μL.
PCR amplification of 10 ng of bisulfite converted genomic DNA was performed using gene specific primers containing the necessary tags for SEQUENOM EpiTYPER (Table S5) . Fast Start PCR master mix (Roche Applied Sciences) was used according to manufacturer's instructions to generate amplicons for downstream EpiTYPER chemistry. Typical PCR cycling by the Australian Genome Research Facility (AGRF) and analyzed according to manufacturer's protocol. Raw β-values and probe intensities were extracted using Illumina Genome Studio Software (data has been deposited into GEO Database with accession number GSE 29189).
We have used three different variants of supervised learning analysis to detect the set of features (probes) critical for discrimination between leukemia and remission bone marrow samples. These were centroid feature selection, linear model for microarray analysis (LIMMA) and recursive feature elimination support vector machine (RFE-SVM). Further details are found in Supplemental Methods. 
Supplemental Material
Supplemental materials may be downloaded here: www.landesbioscience.com/journals/epigenetics/article/20193 conditions performed were: denaturation at 95°C for 10 min followed by 5 cycles of denaturation at 95°C for 10 sec, annealing at 56°C for 20 sec, extension at 72°C for two minutes and 40 cycles of denaturation at 95°C for 10 sec, annealing at 56°C for 20 sec and extension at 72°C for 1.5 min. Successful amplicons were then subjected to SEQUENOM EpiTYPER chemistry consisting of shrimp alkaline phosphatase treatment, RNA transcription and RNase cleavage prior to matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) analysis as outlined in the manufacturer's instructions. Mass spectra were processed using the EpiTYPER viewer software v1.0.5 (SEQUENOM Inc.) and cleaned using an in-house R-script to remove poor quality CpG units and samples. Heatmaps of SEQUENOM data were then drawn using heatmap.2 of the gplots library in R (www.r-project. org).
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